Philippe Georges Aftimos, MD, Institut Jules Bordet, Brussels, Belgium, gives his highlights in the field of breast cancer presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including results from the phase II MAINTAIN study (NCT02632045) of ribociclib plus endocrine therapy after progressing on CDK 4/6 inhibitors. Dr Aftimos additionally highlights results from the phase III DESTINY-Breast04 trial (NCT03734029) of trastuzumab deruxtecan, an antibody-drug conjugate (ADC), in patients with HR+ HER2- advanced breast cancer. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.

свернуть